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Abstract
The development of safe and efficient gene transfer vec-
tors is crucial for the success of gene therapy trials. A
viral vector system promising to meet these require-
ments is based on the apathogenic adeno-associated
virus (AAV-2), a member of the parvovirus family. The
advantages of this vector system is the stability of the
viral capsid, the low immunogenicity, the ability to trans-
duce both dividing and non-dividing cells, the potential
to integrate site specifically and to achieve long-term
gene expression even in vivo, and its broad tropism
allowing the efficient transduction of diverse organs
including the skin. All this makes AAV-2 attractive and
efficient for in vitro gene transfer and local injection in
vivo. This review covers the progress made in AAV vec-
tor technology including the development of AAV vec-
tors based on other serotypes, summarizes the results
obtained by AAV targeting vectors and outlines potential
applications in the field of cutaneous gene therapy.
Copyright © 2004 S. Karger AG, Basel
Introduction
The skin is a very attractive organ for the development
of new therapeutic approaches not only for its easy acces-
sibility, but also for safety issues including the unique pos-
sibility to monitor the treatment site and, in case of side
effects, to excise the affected site, as well as the large num-
ber of different diseases that are principally suitable for
cutaneous gene transfer. Among these opportunities are
genetic immunization, skin cancer, chronic wounds, pri-
mary monogenic skin diseases and systemic diseases char-
acterized by low or absent amounts of circulating proteins
[for review, see Braun-Falco and Hallek, 1998; Watt,
2000; Braun-Falco, 2002; Khavari et al., 2002]. Depend-
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Fig. 1. Schematic description of the AAV-2 genome. The wild-type
AAV-2 genome contains 4,680 nucleotides. The viral promoters (p5,
p19 and p40), the ITR structures and the common polyadenylation
signal are shown at the top. Rep78 and its splice variant Rep68 are
controlled by the p5 promoter and are necessary for viral replication,
transcription and site-specific integration. Rep52 and its splice vari-
ant Rep40 are transcribed from the p19 promoter. They are neces-
sary for packaging the single-stranded genome. The viral capsid pro-
teins (VP1, VP2 and VP3) are controlled from the p40 promoter. The
three capsid proteins differ in their N-termini due to alternative
splicing and different initiation codon usage, but share the VP3
region.
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ing on the disease that should be treated by genetic modu-
lation, the application of a gene transfer vehicle has to ful-
fill distinctive requirements regarding the efficiency of
gene transfer, durability of gene expression, specificity of
the target tissue and safety. The development of such an
efficient and safe vector still remains one of the main hur-
dles to be overcome in the field of cutaneous as well as
general gene therapy.
Although many improvements of non-viral vector sys-
tems have been achieved, viral vectors seem to be more
efficient based on their long evolved strategies for cell
entry. Moreover, for most of the viral systems targeting
strategies have been successfully developed, which is a
major step forward with respect to safety, efficiency and
selectivity [Nicklin and Baker, 2002; Büning et al., 2003;
Thomas et al., 2003]. One of these viral vectors is based
on the adeno-associated virus type 2 (AAV-2). AAV-2 is
currently being used in several human gene therapy trials,
including hemophilia B and cystic fibrosis [Stilwell and
Samulski, 2003]. Especially the long-term gene expression
with mostly no sign of cytotoxic T-cell response to the
AAV capsid or transgene product [Jooss and Chimule,
2003] makes AAV-2 a very promising vector system also
for cutaneous gene therapy.
From Virus to Vector
AAV-2 was discovered as a co-infecting agent during
an adenovirus outbreak. Until now no human disease
caused by AAV-2 has been identified [Blacklow et
al.,1968; Blacklow et al., 1971; Blacklow, 1988]. AAV-2
itself is a single-stranded, replication-deficient DNA virus
consisting of an icosahedral protein capsid and a genome
of 4,680 nucleotides comprising two open reading frames
(ORF) [Carter and Samulski, 2000]. Although genotoxic
agents (e.g. UV irradiation, Á-irradiation, hydroxyurea,
topoisomerase inhibitors, and various chemical carcino-
gens) can support a productive infection [Yalkinoglu et
al., 1988; Yakobson et al., 1989; Yalkinoglu et al., 1991;
Russell et al., 1995] efficient progeny production needs
helper virus functions, normally provided by adenovirus
or herpesvirus. Lacking a helper virus, the virion latently
infects by integrating into the host genome. This integra-
tion occurs in 70% of the cases at a specific locus in the q
arm of human chromosome 19 within 19q13.4 termed
AAVS1 [Kotin et al., 1990; Samulski et al., 1991; Kotin et
al., 1992; Giraud et al., 1994; Dutheil et al., 2000]. For
this unique feature AAV-2 needs the inverted terminal
repeats (ITRs), which are flanking the viral genome on
both sites, and the expression of the viral Rep proteins
Rep78 and Rep68 (fig. 1). These multifunctional proteins
are encoded, together with two additional family mem-
bers (Rep52 and Rep40), in the 5) ORF of the viral
genome. The 3) ORF accommodates (fig. 1) the three cap-
sid proteins VP1 (90 kD), VP2 (72 kD) and VP3 (60 kD).
They share overlapping sequences and differ only at their
N-termini, building the AAV-2 capsid with a relative stoi-
chiometry of about 1:1:20 [Rabinowitz and Samulski,
2000].
Both ORFs are normally replaced by the transgene,
since the only cis elements necessary for the generation of
recombinant AAV-2 vectors (rAAV-2) are the viral ITR
structures (fig. 2) [Carter and Samulski, 2000]. These ‘gut-
less’ vectors are no longer able to integrate site specifical-
ly, since the Rep proteins are missing. Although Nakai et
al. [2003] observed that random integration into active
genes in vivo occurs, these are very rare events. The
majority of rAAV-2 genomes remain in an episomal state
[Nakai et al., 2001; Schnepp et al., 2003]. However, there
is the possibility to integrate ITR-flanked transgenes site
specifically into the human chromosome 19 by providing
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Fig. 2. Schematic description of wild-type
and recombinant AAV-2. For the produc-
tion of rAAV-2 both open reading frames
(Rep and Cap) of the wild-type AAV genome
are replaced by the transgene. Therefore, the
viral functions (integration, replication and
new viral production) are lost in rAAV-2,
which, as a ‘gutless’ vector, is shuttling the
transgene into the cell.
the Rep coding sequence in cis or in trans [Balague et al.,
1997; Surosky et al., 1997; Huttner et al., 2003b].
Although packaging cell lines for the production of
rAAV-2 have been described [Liu et al., 2000; Qiao et al.,
2002a, 2002b], rAAV-2 are still mostly produced by trans-
fection. Until the cloning of adenoviral helper plasmids
(e.g. pXX6 or pDG) [Grimm et al., 1998; Xiao et al.,
1998], which encodes adenoviral genes necessary for
rAAV-2 production, rAAV-2 vectors were generated by
transfection of a vector plasmid (encodes the transgene
flanked by ITRs) and an AAV-2 helper plasmid (provides
Rep and capsid proteins) into HeLa or 293 cells followed
by infection with a helper virus (adenovirus or herpesvi-
rus) [Ferrari et al., 1997; Girod et al., 1999]. Now, the
helper virus can be substituted by the adenoviral helper
plasmids thus avoiding helper virus contamination
[Grimm et al., 1998; Xiao et al., 1998; Grimm et al.,
1999]. Furthermore, improvements in the purification
protocols using iodixanol gradients and/or heparin affini-
ty chromatography resulted in rAAV-2 preparation of
high titer (11010 transducing rAAV-2/ml) and purity.
AAV Serotypes
AAV-2 was the first serotype from which recombinant
vectors could be produced and from which the atomic
structure has been determined by X-ray crystallography
[Xie et al., 2002]. In the meantime, eight serotypes (AAV-
1 to AAV-8) have been identified. Sequence comparison
among them revealed the greatest divergence in the cap-
sid proteins [Rabinowitz and Samulski, 2000; Gao et al.,
2003; Stilwell and Samulski, 2003] and here especially in
the regions responsible for antibody and receptor binding.
This leads to differences in both tropism [Halbert et al.,
2001; Gao et al., 2002; Ding et al., 2003; Grimm et al.,
2003] and serological neutralization [reviewed in Sun et
al., 2003]. Pseudotyping techniques were developed,
which allow to package expression cassettes flanked by the
AAV-2 ITRs into capsids of alternative serotypes [Gao et
al., 2002; Rabinowitz et al., 2002; Grimm et al., 2003].
This allows to optimize gene delivery for selected applica-
tions and may circumvent problems with preexisting im-
munity.
Hauck et al. [2003] generated chimeric viruses and
combined the abilities of different serotypes. They pro-
duced AAV-1/AAV-2 chimeras and could purify these
viruses by heparin chromatography (ability obtained
from AAV-2) and could efficiently transduce muscle
(ability obtained from AAV-1) and liver cells (ability
obtained from AAV-2) in vivo. However, until now only
receptors for AAV-2, -4 and -5 are described. Heparan
sulfate proteoglycan (HSPG), a widely distributed cell
surface molecule, was identified as the primary receptor
for AAV-2 and is bound by AAV-3 as well [Summerford
and Samulski, 1998; Rabinowitz et al., 2002], whereas
sialic acid seems to be the attachment receptor for AAV-4
(· 2-3 O-linked) and AAV-5 (· 2-3 N-linked) [Kaludov et
al., 2001]. Mutational analysis and the determination of
the three-dimensional structure made it possible for
AAV-2 to assume how the capsid interacts with the glycan
moiety of HSPG and to identify the arginine residues
R585 and R588 in the AAV-2 capsid as the essential resi-
dues in this interaction [Xie et al., 2002; Opie et al.,
2003]. For all the other serotypes this remains still un-
clear.
AAV-2 Infectious Biology
Many steps of the virus:cell interaction are still un-
known. However, a model has been developed, based on
results obtained with the cervix carcinoma cell line HeLa.
Single virus tracing measurements showed that AAV-2
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moves in solution by free diffusion and that in the vicinity
of the cell, the velocity of AAV-2 decelerates [Seisenberger
et al., 2001]. After repetitive contacts with the cell mem-
brane AAV-2 binds to the negatively charged HSPG on
the cell surface [Summerford and Samulski, 1998; Seisen-
berger et al., 2001]. This attachment is enhanced by fibro-
blast growth factor receptor 1 binding [Qing et al., 1999].
After interaction with ·vß5 integrins [Summerford et al.,
1999], AAV-2 enters the cell by a receptor-mediated
endocytosis through clathrin-coated pits [Duan et al.,
1999; Bartlett et al., 2000]. Activation of the small GTP-
binding protein Rac1, which is assumed to be mediated
by the integrin binding, leads to the stimulation of the
phosphatidylinositol-3-kinase pathway [Sanlioglu et al.,
2000]. This stimulation results in rearrangements of the
cytoskeleton, which allows the trafficking of AAV-2-con-
taining endosomes [Sanlioglu et al., 2000]. After acidifica-
tion, AAV-2 is released from the endosomes at the late
endosomal stage [Douar et al., 2001] and reaches the
nucleus probably via the nuclear pore complexes. In the
nucleus the viral genome is replicated or integrated into
the host cell genome depending on the presence or ab-
sence of a helper virus. For the AAV-2-based vectors it is
assumed that they infect the cell using the same steps;
however neither replication nor site-specific integration
can occur.
Basic Aspects of rAAV-Mediated Transduction
of Keratinocytes
In the past, AAV-2 vectors have been tested for effica-
cy in a variety of different cell types with variable success
[Maass et al., 1998]. For example, cells originating from
muscle, brain, liver, and bronchial epithelia turned out to
be highly permissive for AAV-2 infection [Xiao et al.,
1996; Snyder et al., 1997; During et al., 1998; Guy et al.,
1999; Herzog et al., 1999; Sanlioglu et al., 2001], whereas
cells of the megakaryocytic origin or vascular endothelial
cells showed only low transduction efficiencies [Ponnaz-
hagan et al., 1996, 1997; Nicklin et al., 2001]. This
explains why the first clinical trials using AAV-2 as a vec-
tor were approved for treatment of hemophilia by target-
ing the liver and muscles [Manno et al., 2003] (informa-
tion by Avigen), for Parkinson disease by vector injection
into the striatum [During et al., 2001] (information by
Avigen) and for cystic fibrosis by transfection of bronchial
epithelia [Flotte et al., 2003; Moss et al., 2004].
rAAV-mediated gene transfer into the skin has been
demonstrated with considerable efficacy as well. For ex-
ample, in an in vitro setting, rAAV-2 allowed transduc-
tion of up to 70% of primary human keratinocytes, the
preponderant cell type of the epidermis (fig. 3) [Braun-
Falco et al., 1999], indicating that the cells are per se per-
missive for rAAV vector particles. In vivo gene transfer
into porcine skin has been successfully demonstrated by
Hengge and Mirmohammadsadegh [2000] after intrader-
mal injection of rAAV particles, which let to a transgene
expression in epidermal keratinocytes and adnexal struc-
tures for more than 6 weeks. In mice, subcutaneous injec-
tion of rAAV particles resulted in a durable transgene
expression within the panniculous carnosus that lasted for
several months [Donahue et al., 1999].
It is not surprising that human keratinocytes are per-
missive for rAAV-2, since they express HSPG on their
surface as well as members of the fibroblast growth factor
receptor family and integrins, all the rAAV receptors nec-
essary for binding and uptake of vector particles through
the cell membrane [Kim et al., 1994; Marchese et al.,
1997; Lundqvist and Schmidtchen, 2001]. However, the
susceptibility of keratinocytes for AAV-2 in relation to the
highly permissive HeLa cells seems relatively low. An
impaired intracellular trafficking of rAAV due to ubiqui-
tination of viral particles has been shown in some cell
types to limit high-efficient transduction [Duan et al.,
2000b; Hansen et al., 2000]. This may also be true at least
in part for keratinocytes [unpubl. data]. Nevertheless, this
barrier can be overcome by decreasing ubiquitination
using proteasome inhibitors. Since proteasome inhibitors
are currently under investigation as anti-cancer agent in
phase I and II human trials, so far with good safety pro-
files at active doses [Adams, 2002], they may be suitable
for clinical application as rAAV-2 enhancers.
Another point to consider in the infectious process is
the role of the epidermal growths factor receptor tyrosine
kinase (EGFR TK). After entering the nucleus, conver-
sion of the single-stranded viral DNA into a transcription-
ally active double-stranded conformation is known to be
the rate-limiting step before transgene expression can
occur. The activity of this process has been found to corre-
late with the phosphorylation state of a cellular tyrosine
phosphoprotein, designated single-stranded D-sequence-
binding protein [Qing et al., 1998]. The phosphorylation
of this protein itself is regulated by EGFR TK in a way
that specific inhibition of EGFR TK finally results in an
enhancement of transgene expression [Mah et al., 1998;
Smith et al., 2003]. Since members of the EGF family
represent major autoregulatory factors for keratinocytes
driving cell proliferation, modulating terminal differenti-
ation and controlling epidermal homeostasis [Pittelkow et
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Fig. 3. High-efficient gene transfer of human keratinocytes with
rAAV-2 containing the gene for ß-galactosidase (blue cells).
Fig. 4. Clonal growth of rAAV-2/green fluorescent protein trans-
duced keratinocytes. Keratinocytes were transduced with rAAV-2
containing the gene for green fluorescent protein and cultured at
clonal density over several passages. Shown are passages 2–4 at days
11 (a), 19 (b) and 27 (c) after transduction, each exhibiting clonal
growth of green fluorescent keratinocytes.
al., 1993; Peus et al., 1997], they may also influence the
transduction of keratinocytes with rAAV vectors. Prelimi-
nary work points to this regulator role of EGFR TK [un-
publ. data].
Such basic aspects help to optimize the transduction
process of rAAV vectors into keratinocytes for the various
indications of cutaneous gene therapy.
Application of rAAV Vectors in Cutaneous
Gene Therapy
Among the different areas of cutaneous gene therapy,
the acceleration of wound healing by gene transfer of
growth factors has gained increasing interest in recent
years [Braun-Falco, 2002]. Since the regulatory role of a
number of cytokines has been elucidated within the dif-
ferent stages of normal wound healing [Goldman, 2004],
great expectations have been laid in the topical applica-
tion of recombinant growth factors. So far, only recombi-
nant platelet-derived growth factor has been approved for
the treatment of leg ulcers [Goldman, 2004]. The main
drawback of the topical application of growth factors is
their short half-life, fast degradation by proteases within
the wound fluid and poor availability from ointments.
These problems might be overcome by direct transfer of
growth factor genes into the granulation tissue which may
lead to a more sustained expression and profound effect
of growth factors. AAV-2 vectors have already been
applied for wound healing approaches with promising
results. AAV-2-mediated gene transfer of vascular endo-
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Table 1. Candidate genodermatoses for
rAAV-mediated gene augmentation therapy Disease Gene defect Functional cDNA
length (")
X-linked ichthyosis steroid sulfatase 1,550
Lamellar ichthyosis transglutaminase 1 2,450
Sjögren-Larsson syndrome fatty aldehyde dehydrogenase 1,550
Junctional epidermolysis bullosa laminin 5 Á2 chain (LAMC2) 1,900 (truncated)
Ehlers-Danlos type VI lysyl hydroxylase 1 2,100
Refsum syndrome phytanoyl-coenzyme A hydroxylase 1,050
Gaucher syndrome glucocerebrosidase 1,650
Papillon-Lefevre/Haim-Munk
syndrome cathepsin C 1,900
Albinism type I tyrosinase 1,600
Congenital erythropoietic
porphyria uroporphyrinogen III synthase 1,300
Xeroderma pigmentosum XP-A, -B, -C, -D 910, 2,400, 2,500,
2,400
thelial growth factor has shown to stimulate angiogenesis
and wound healing in incisional skin wounds in diabetic
mice, in experimental burn wounds in mice and in exci-
sional wounds in rats [Deodato et al., 2002; Galeano et al.,
2003a, 2003b].
Another application might be inherited diseases. Since
AAV-2 vectors have shown to mediate long-term gene
expression in animal models for more than 1 year in sev-
eral organs (e.g. in muscles and neuronal tissue), they
might be particularly useful for treatment approaches of
genodermatoses, in which durable correction of the un-
derlying genetic abnormality is necessary to achieve clini-
cal benefit. In recent years, significant progress has been
made in the molecular characterization of an increasing
number of genodermatoses [Irvine and McLean, 2003].
Many of them have their underlying defect within the epi-
dermis. The epidermis is known to be a lifelong self-
renewing tissue comprising stem cells within their basal
layer, which upon division generates a new stem cell and a
daughter cell that undergoes terminal differentiation [for
review, see Watt, 2000]. In order to achieve durable gene
expression the necessity to target keratinocyte stem cells is
quiet obvious, otherwise gene expression will be lost after
one epidermal turnover in approximately 4 weeks, inde-
pendent on efficacy or integration. There are several ways
to identify cells, which might have the potential to be a
stem cell; even not a single is definitely specific. One in
vitro possibility is to look for clonal growth properties
[Barrandon and Green, 1987; Jones and Watt, 1993]. Fig-
ure 4 shows one of our own experiments, in which human
keratinocytes have been transduced with rAAV-2 vector
particles carrying green fluorescent protein as transgene,
thus allowing to follow growth properties of transduced
cells cultured in the absence of a feeder layer. Without any
selective pressure, transduced keratinocytes were able to
form clones even after several passages and several weeks
of culture indicating that keratinocytes with stem cell
growth characteristics have been originally transduced.
Even rAAV-2 vectors may be able to transduce kerati-
nocyte stem cells, one drawback may be a rapid vector
dilution in rapidly dividing tissues in the absence of vec-
tor integration. Long-term transgene expression in mus-
cle, for example, has not been attributed to integration,
but primarily to the extremely low dividing rate of these
particular tissue prolonging the dilution effect of non-
integrated episomal forms of the vector genome [Duan et
al., 1998]. Although keratinocyte stem cells are known in
vivo, in contrary to cultivation ex vivo, for having a very
slow cell cycle, they still may have a higher proliferation
rate than muscle tissue. Nevertheless, in airway epithelial
cells, which have with 3–5 days a higher turnover rate
than the epidermis, rAAV-mediated transgene expression
persisted in vivo for more than 150 days [Duan et al.,
2000b], allowing the speculation that gene expression
from transduced epithelial stem cells may be more stable
than from non-stem cells.
Which genodermatoses could theoretically be targeted
with AAV-2 vectors? In principle the same genoderma-
toses as the ones considered candidate diseases for retro-
or lentiviral gene transfer, as long as the expression cas-
sette containing the therapeutic gene does fit into the
AAV-2 capsid with a packaging capacity of approximately
4.5 kb. At first, a packaging capacity of 4.5 kb may appear
as a considerable limitation, but even in a construct con-
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taining an endogenous promoter, e.g. a cytokeratin 14
promoter with a length of around 2 kb, therapeutic
sequences up to 2.5 kb can be inserted and packaged.
Table 1 gives a selection of recessive genodermatoses with
cDNA size below 2.5 kb. Besides that, new developments
have allowed to overcome the vector size limitation
through viral DNA heterodimerization [Duan et al.,
2000a; Sun et al., 2000]. This strategy relies on a unique
feature of the rAAV-2 biology to form intermediate circu-
lar concatamers of two independent vector templates.
Thus, a large gene and its endogenous promoter can be
split into two individual rAAV vectors. After co-transfec-
tion of the target cell, the two vectors form head-to-tail
heterodimers through identical sequence homology of the
ITRs resulting in a rejoining of the split parts.
Our own work has focused on the Sjögren-Larsson syn-
drome, a neurocutaneous disease clinically characterized
by generalized ichthyosis, mental retardation and spastic
diplegia or tetraplegia. It is caused by an autosomal reces-
sive defect in the gene coding for fatty aldehyde dehydro-
genase (FALDH), an enzyme necessary for the oxidation
of long-chain aliphatic aldehydes to fatty acids [Rizzo et
al., 2001]. Using an AAV-2 vector containing the func-
tional cDNA for FALDH, the FALDH activity in an
FALDH-negative cell line may be increased to a level of
heterozygous carriers which are phenotypically not al-
tered [unpubl. data].
Besides gene augmentation and restoration approaches
for recessive disorders, rAAV-2 may be applicable to
dominant diseases as well. There are different in situ
repair and silencing strategies under development, e.g. the
use of small DNA/RNA chimeric molecules, ribozymes,
antisense nucleic acids or inhibitory RNA oligonucleo-
tides [Khavari et al., 2002]. Theoretically, AAV-2 vectors
may be suitable to deliver each of these genetic molecules.
The successful rescue of a dominant rhodopsin mutation
in rat photoreceptor cells through rAAV-2-mediated ribo-
zymes has already been demonstrated [LaVail et al.,
2000]. Moreover, AAV-2 seems capable to introduce spe-
cific genetic modifications at homologous chromosomal
sequences in a gene targeting process, thus being able to
correct substitutions, insertion and deletion mutations
[Hirata and Russell, 2000].
Another potential application of cutaneous gene thera-
py uses the skin as a ‘bioreactor’. Ideally, a circumscribed
area of the body surface should be directly transduced or
transplanted with genetically modified keratinocytes,
leading to the production of a certain therapeutic gene
product that passes the dermal-epidermal junction,
reaches the bloodstream and is distributed in the circula-
tion. This ‘bioreactor’ approach could be applicable to
diseases with reduced or absent systemic proteins, e.g.
hemophilia or anemia. For example, the subcutaneous
injections of AAV-2 vectors encoding factor IX revealed
long-term protein expression in the serum of mice for at
least 1 year [Donahue et al., 1999]. In a nude mice model,
AAV-2-transduced epidermal cells secreted erythropoie-
tin, which was delivered systemically and resulted in an
increased hematocrit [Descamps et al., 1996]. The great
advantage of this approach in comparison to liver-
directed gene delivery or intravenous injection of vector
particles, for example, is that the modified skin can easily
be monitored and excised in case of unexpected adverse
effects.
Targeting of AAV-2 Vectors
Targeting of vectors to a particular tissue or cell type is
an important issue to enhance the specificity of any thera-
peutic effect. For instance, in metastatic malignant mela-
noma, direct injection of cytokine-containing vectors into
subcutaneous metastases might reduce tumor size locally,
but usually lacking any systemic effect [Penel and Bonne-
terre, 2003]. Therefore, the target delivery of immunomo-
dulatory genes specifically to tumor cells, unsystematical-
ly distributed within the whole body, will greatly improve
an anti-tumor response. For the treatment of genoderma-
toses the importance of keratinocyte stem cell transduc-
tion has already be mentioned. Targeting approaches may
facilitate this necessity. Targeting of AAV vectors can be
performed at least at two levels, namely at the virus entry
into the cells and at the transcriptional level. Here, we will
focus on the receptor targeting approach, in which se-
lective binding and entry only into the desired cell type is
the rewarding task. Until now two different strategies –
direct and indirect targeting [Cosset and Russell, 1996] –
have been used to reach this goal.
The indirect targeting to a cell-specific receptor is
mediated by an associated molecule, which is bound to
the viral surface and interacts with a specific cell surface
molecule [Miller, 1996]. Bartlett et al. [1999] used a bispe-
cific antibody, which recognized simultaneously ·IIbß3
integrin and the intact AAV-2 capsid. They employed this
approach successfully for the transduction of MO7e and
DAMI cells, which are not permissive for wild-type
AAV-2 infection. Recently, Ponnazhagan et al. [2002]
described another elegant approach for indirect targeting
by using avidin-linked ligands conjugated to biotinylated
rAAV-2 for the transduction of the human ovarian cancer
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cell line SKOV3.ip1 and like Bartlett et al. [1999] for the
transduction of the AAV-2-refractory megakaryocytic cell
line MO7e via EGFR and fibroblast growth factor recep-
tor 1·, respectively.
In the direct targeting strategy, a ligand- or receptor-
specific single chain antibody is directly inserted into the
viral capsid [Walter and Stein, 1996]. For AAV-2 it was
shown that the inserted sequence is functional, when it is
either fused to the N-terminus of VP2 [Yang et al., 1998;
Wu et al., 2000] or inserted between amino acids 587 and
588 or after 588 in the VP3 region of the capsid [Girod et
al., 1999; Grifman et al., 2001; Nicklin et al., 2001; Shi et
al, 2001; Shi and Bartlett, 2003]. Other sites in the capsid
have also been described, e.g. 161 (in the VP2 region), 459
and 584 (in the VP3 region), who are able to display an
inserted sequence, but the functionality remains to be
proven [Shi et al., 2001]. However, until now the most
promising site for the insertion of a functional ligand is
587/588. Since the VP3 region is also found in the VP2
and VP1 capsid proteins (fig. 1), a sequence inserted at
this site is displayed 60 times on the AAV-2 capsid. The
three-dimensional structure reveals that 587 is exposed at
the viral surface, lying at the side of the peak, which forms
the threefold symmetry axis. This site was first described
by Girod et al. [1999], who inserted the L14 peptide
which contains the RGD motif of the laminin fragment
P1 [Aumailley et al., 1990] C-terminal of 587, and used
the generated targeting vector to efficiently transduce
B16F10 (mouse melanoma) and RN22 (rat Schwannoma)
cell lines, which were not infected by wild-type AAV-2.
The same site was also successfully used for the insertion
of an endothelial-specific peptide isolated by phage dis-
play. By this, an AAV-2 targeting vector which is able to
efficiently infect endothelial cells, e.g. human umbilical
vein endothelial cells and human saphenous vein endo-
thelial cells, was developed [Nicklin et al., 2001]. Using a
CD13-specific peptide, which binds to the NGR receptor
expressed on angiogenic vasculature and on many tumor
cell lines, with the sequence NGRAHA for insertion
between 587 and 588, Grifman et al. [2001] were able to
target AAV-2 to KS1767 (Kaposi sarcoma) and RD (rhab-
domyosarcoma) cells. Ried et al. [2002] used this site to
generate a universal targeting vector by using a truncated
version (Z34C) of the immunoglobulin-binding domain
from protein A of Staphylococcus aureus [Ohno et al.,
1997] as a coupling module. This coupling module can be
used to bind cell-selective/-specific antibodies [Ried et al.,
2002]. That this region works also in vivo could be shown
by Shi and Bartlett [2003]. By insertion of a RGD-4C
motif C-terminal of 588, which mediates the binding to ·v
integrins, they generated an AAV-2 targeting vector which
showed a clear enhancement in the transduction of
SKOV-3 cells injected intraperitoneally into immunodefi-
cient mice in comparison to unmodified AAV-2 vectors.
Furthermore, White et al. [2004] showed that the AAV
tropism can be genetically engineered by the use of phage
display-derived peptides to generate vectors that are se-
lective for the vasculature in vivo.
Since one characteristic of keratinocyte stem cells is a
high ß1-integrin (CD29) expression [Jones and Watt,
1993], the use of this targeting vector together with anti-
human CD29 antibodies may be a favorable strategy for
targeting keratinocyte stem cells. For targeting malignant
melanoma cells the EGFR may be a candidate even
though expression is not solely restricted to melanoma
cells.
Recently, Perabo et al. [2003] developed another
promising technique, the adeno-associated virus display,
to generate receptor-specific AAV-2 targeting vectors by a
combinatorial approach. This new technology uses a
library of AAV-2 capsid mutants carrying a randomized
7-mer peptide between 587 and 588 to select for receptor-
specific AAV-2 capsid mutants. This library was used to
infect the target cell line and was screened for capsid
mutants who are able to infect and replicate in the target
cells. After five selection rounds on the AAV-2 non-per-
missive cell line MO7e, Perabo et al. [2003] isolated an
AAV-2 capsid mutant bearing the sequence RGDAVGV
between 587 and 588. They could show that this se-
quence, when inserted between 587 and 588 of rAAV-2,
confers the targeting vector with the ability to infect the
target cell line MO7e efficiently in a receptor-specific
manner. Applying the same approach on a B-cell chronic
lymphocytic leukemia cell line (Mec1) resulted in a target-
ing vector able to efficiently infect cells of patients with
B-cell chronic lymphocytic leukemia, which are refractory
to AAV-2 infection. These new techniques will have enor-
mous implications for the development of targeting
AAV-2 vectors, as peptides are preselected within the
architectural environment of AAV capsids for their tar-
geting capacity without the need to know the respective
cell surface molecule which mediates the binding and
uptake into the targeting cell. This is important especially
in the field of cutaneous gene therapy, where only a few
cell surface molecules are known to be able to serve as
targets of receptor-specific vectors.
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Future Prospects
With the discovery and utilization of the different sero-
types, the improvements in vector production, the devel-
opment of the AAV targeting technology and the determi-
nation of the three-dimensional structure of the AAV cap-
sid, AAV-based vectors have developed to the vector sys-
tem of choice for many applications including those of
cutaneous gene therapy. However, there are still some
limitations to be overcome. The quality of gene transfer
concerning efficacy, duration of transgene expression and
specific cell targeting still needs improvements for kerati-
nocytes as well as malignant melanoma cells. Even though
targeting vectors might be able to infect these cells in a
receptor-specific manner, in most cases this transduction
ability is not limited to one cell type. In addition, preexist-
ing and newly generated neutralizing antibodies to the
AAV-2 capsid are a hurdle at least for repeated vector
applications. This can may be avoided by the use of differ-
ent serotypes, which do not cross react, or the use of tar-
geting vectors [Huttner et al., 2003a]. Forcing integration
at a specific chromosomal location opposing the observa-
tion of random integration in actively transcribed genes is
a point which needs to be further analyzed. However, the
methods for further improvements are there and will
result in second- and third-generation rAAV vectors us-
able for efficient, safe and selective gene therapy applica-
tions.
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